What is Sofie Biosciences?
Sofie Biosciences is at the forefront of advancing molecular imaging, aiming to transform clinical diagnostics and therapeutics by enhancing the understanding and treatment of disease biology. The company is dedicated to increasing the adoption and application diversity of theranostics, thereby removing the traditional barriers of cost and complexity. Through its comprehensive suite of imaging and radiochemistry systems, coupled with a premier radiopharmacy network and contract manufacturing capabilities for novel diagnostic and therapeutic agents, Sofie Biosciences is committed to improving patient health outcomes.
How much funding has Sofie Biosciences raised?
Sofie Biosciences has raised a total of $55.6M across 6 funding rounds:
Series A
$5M
Grant
$1.5M
Private Equity
$3.7M
Series B
$16M
Debt
$2M
Series C
$27.4M
Series A (2013): $5M with participation from Tata Industries, Cycad Group, and MRM Capital
Grant (2014): $1.5M led by MRM Capital and Cycad Group
Private Equity (2016): $3.7M supported by Artiman Managment, LLC
Series B (2018): $16M featuring Mayor Richard Riordan
Debt (2020): $2M backed by PPP
Series C (2020): $27.4M with participation from Jubilant Pharma Limited
Key Investors in Sofie Biosciences
MRM Capital
MRM Capital Holdings specializes in providing creative private equity solutions and strategic advisory services, focusing on raising capital and debt solutions for various investment opportunities, particularly in real estate and distressed debt. They target smaller, middle-market companies and high net worth individuals.
Cycad Group
Cycad Group invests in technology across sectors like healthcare and energy, supporting companies with innovative solutions in medical devices and biopharmaceuticals. Their strategy emphasizes leveraging cutting-edge technology to create impactful products and services.
Tata Industries
Tata Industries is part of the Tata Group, a prominent conglomerate involved in diverse sectors including automotive manufacturing, technology, and consumer goods. Their investment focus often aligns with innovation and strategic growth across their extensive business verticals.
What's next for Sofie Biosciences?
With substantial enterprise-level backing, Sofie Biosciences is poised for accelerated expansion and innovation. The company's strategic focus will likely involve scaling its operational infrastructure, further developing its theranostic platforms, and broadening its market reach. Continued investment in research and development is anticipated to drive the creation of new imaging agents and therapeutic solutions, solidifying Sofie Biosciences' position as a leader in the theranostics field and potentially exploring new applications for its technology in both clinical and research settings.
See full Sofie Biosciences company page
